Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506)

Clinical Immunology

Volumn 90, Issue 1, 1999, Pages 133-140

  Chen, Yung Wu ^a   Smith, Morey L ^a   Sheets, Michael P ^a   Ballaron, Stephen J ^a   Trevillyan, James M ^a   Fey, Thomas A ^a   Gauvin, Donna M ^a   Kolano, Robin ^a   Pong, Melissa S ^a   Hsieh, Gin C ^a   Bauch, Joy ^a   Marsh, Kennan ^a   Carter, George ^a   Luly, Jay ^a   Djuric, Stevan ^a   Mollison, Karl W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Ex vivo; FK506; IL 2; Immunosuppression; Pigs

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; IMMUNOPHILIN; INTERLEUKIN 2; IONOMYCIN; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETOGENESIS; DRUG ACTIVITY; DRUG BINDING; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SWINE; T LYMPHOCYTE;

EID: 0032938122     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4625     Document Type: Article

References (45)

1. Almond G. W. Research applications using pigs. Vet. Clin. N. Am. Food Anim. Pract. 12:1996;707-716.
2. Pescovitz M. D., Lunney J. K., Sachs D. H. Murine anti-swine T4 and T8 monoclonal antibodies: Distribution and effects on proliferative and cytotoxic T cells. J. Immunol. 134:1985;37-44.
3. Saalmuller A., Bryant J. Characterization of porcine T lymphocytes and T-cell lines. Vet. Immunol. Immunopathol. 43:1994;45-52.
4. +. Immunol. 81:1994;578-583.
5. ---. Eur. J. Immunol. 20:1990;265-269.
6. Saalmuller A., Hirt W., Reddehase M. J. Porcine gamma/delta T lymphocyte subsets differing in their propensity to home to lymphoid tissue. Eur. J. Immunol. 20:1990;2343-2346.
7. +. Immunology. 77:1992;219-227.
8. +. Vet. Immunol. Immunopathol. 43:1994;69-77.
9. Siekierka J. J., Sigal N. H. FK-506 and cyclosporin A: Immunosuppressive mechanism of action and beyond. Curr. Opin. Immunol. 4:1992;548-552.
10. Kahan B. D. Cyclosporin: The base for immunosuppressive therapy - Present and future. Transplant. Proc. 25:1993;508-510.
11. Starzl T. E. FK506 versus cyclosporine. Transplant. Proc. 25:1993;511-512.
12. McMaster P., Buist L. FK 506 in transplantation. Transplant. Proc. 25:1993;2684-2685.
13. Morris R. E. Mechanisms of action of new immunosuppressive drugs. Ther. Drug Monit. 17:1995;564-569.
14. Elmer D. S., Nyman T., Hathaway D. K., Alloway R., Gaber A. O. Use of FK506 immunosuppressive therapy in pancreas transplantation. J. Transpl. Coord. 6:1996;122-127.
15. Shapiro R. Tacrolimus (FK506) in kidney transplantation. Transplant. Proc. 29:1997;45-47.
16. Spencer C. M., Goa K. L., Gillis J. C. Tacrolimus, An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 54:1997;925-975.
17. Ho S., Clipstone N., Timmermann L., Northop J., Graef I., Fiorentino D., Nourse J., Crabtree G. R. The mechanism of action of cyclosporine A and FK506. Clin. Immunol. Immunopathol. 80:1996;S40-S45.
18. Schreiber S. L., Crabtree G. R. The mechanism of action of cyclosporin A and FK506. Immunol. Today. 13:1992;136-142.
19. Halloran P. F. Molecular mechanisms of new immunosuppressants. Clin. Transplant. 10:1996;118-123.
20. p. J. Biol. Chem. 271:1996;1274-1277.
21. p. J. Biol. Chem. 268:1993;3747-3752.
22. Fruman D. A., Klee C. B., Bierer B. E., Burakoff S. J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporinA. Proc. Natl. Acad. Sci. USA. 89:1992;3686-3690.
23. Clipstone N. A., Crabtree G. R. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature. 357:1992;695-697.
24. Su Q., Weber L., Le Hir M., Zenke G., Ryffel B. Nephrotoxicity of cyclosporin A and FK506: Inhibition of calcineurin phosphatase. Ren. Physiol. Biochem. 18:1995;128-139.
25. Klintmalm G. B., Gonwa T. A. Nephrotoxicity associated with cyclosporin and FK506. Liver Transplant Surg. 1:1995;11-19.
26. Shaw L. M., Kaplan B., Kaufman D. Toxic effects of immunosuppressive drugs: Mechanisms and strategies for controlling them. Clin. Chem. 42:1996;1316-1321.
27. Shaw L. M., Brayman K. L. FK-506 therapeutic drug monitoring. Clin. Chem. 40:1994;2207-2208.
28. Yatscoff R. W., Langman L. J., LeGatt D. F. Pharmacodynamic monitoring of immunosuppressive drugs. Transplant. Proc. 28:1996;3013-3015.
29. Yatscoff R. W., Aspeslet L. J., Gallant H. L. Pharmacodynamic monitoring of immunosuppressive drugs. Clin. Chem. 44:1998;42-432.
30. Tsunoda S. M., Aweeka F. T. The use of therapeutic drug monitoring to optimize immunosuppressive therapy. Clin. Pharmacokinet. 30:1996;107-140.
31. Shaw L. M., Kaplan B., Brayman K. L. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin. Chem. 44:1998;381-387.
32. Batiuk T. D., Pazderka F., Enns J., De Castro L., Halloran P. F. Cyclosporine inhibition of leukocyte calcineurin is much less in whole blood than in culture medium. Transplantation. 61:1996;158-161.
33. Batiuk T. D., Pazderka F., Halloran P. F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 59:1995;1400-1404.
34. Batiuk T. D., Kung L., Halloran P. F. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J. Clin. Invest. 100:1997;1894-1901.
35. Kino T., Hatanaka H., Hashimoto M., Nishiyama M., Goto T., Okuhara M., Kohsaka M., Aoki H., Imanaka H. FK-506, a novel immunosuppressant isolated fromA. streptomyces. J. Antibiot. 40:1987;1249-1255.
36. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: Parameters of production and a quantitative microassay for activity. J. Immunol. 120:1978;2027-2032.
37. Hewlett G., Stunkel K. G., Schlumberger H. D. A method for the quantitation of interleukin-2 activity. J. Immunol. Methods. 117:1989;243-246.
38. Nagase K., Iwasaki K., Nozake K., Noda K. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J. Pharm. Pharmacol. 46:1993;113-117.
39. Collins R. A., Tayton H. K., Gelder K. I., Britton P., Oldham G. Cloning and expression of bovine and porcine interleikin-2 in baculovirus and analysis of species cross-reactivity. Vet. Immunol. Immunopathol. 40:1994;313-324.
40. Kelley K. W. Cross-talk between the immune and endocrine systems. J. Anim. Sci. 66:1988;2095-2108.
41. Morrow-Tesch J. L., McGlone J. J., Salak-Johnson J. L. Heat and social stress effects on pig immune measures. J. Anim. Sci. 72:1994;2599-2609.
42. McGlone J. J., Salak J. L., Lumpkin E. A., Nicholson R. I., Gibson M., Norman R. I. Shipping stress and social status effects on pig performance, plasma cortisol, natural killer cell activity and leukocyte numbers. J. Anim. Sci. 71:1993;888-896.
43. Salak-Johnson J. L., McGlonme J. J., Norman R. L. In vivo glucocorticoid effects on porcine natural killer cell activity and circulating leukocytes. J. Anim. Sci. 74:1996;584-592.
44. Shirakata Y., Kobayashi M., Ohtsuka K., Sugano M., Terajima H., Ikai I., Okajima H., Egawa H., Inomata Y., Inamoto T., Tanaka K., Yamaoka Y. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. Transplantation. 60:1995;1582-1587.
45. Shiraga T., Matsuda H., Nagase K., Iwasaki K., Noda K., Yamazaki H., Shimada T., Funae Y. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47:1994;727-735.